CPRX - Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 82
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Patrick J. McEnany | Co-Founder, Chairman, Pres & CEO | 1.2M | N/A | 1947 |
| Ms. Alicia Grande C.M.A., CPA, CMA, CPA | Chief Accounting Officer, VP, Treasurer & CFO | 667.91k | N/A | 1971 |
| Dr. Steven R. Miller Ph.D. | COO & Chief Scientific Officer | 809.03k | N/A | 1962 |
| Dr. Gary Ingenito M.D., Ph.D. | Chief Medical & Regulatory Officer | 751.85k | N/A | 1956 |
| Mr. Jeffrey Del Carmen | Chief Commercial Officer | 711.7k | N/A | 1971 |
| Ms. Mary Coleman | VP & Head of Investor Relations | N/A | N/A | N/A |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | N/A | N/A | 1964 |
| Mr. Pete Curry Sr. | VP of Sales | N/A | N/A | N/A |
| Dr. Stanley Iyadurai M.D., Ph.D. | Sr. VP of Medical Affairs & Drug Discovery | N/A | N/A | N/A |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | N/A | N/A | 1976 |
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Corporate Governance
Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 30, 2023 is 5. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 3; Compensation: 5.
